Emma is currently the Head of Global Digital Health Technology Innovation at Amgen. In her capacity she is overseeing medical excellence and the digital transformation across the organization, focusing on new ways of working through streamlining process, delivering new/enhanced systems and driving capability build and engagement.

Troels Sørensen has over 25 years of experience in the pharmaceutical industry with a unique broad profile across gene therapy, biologic, and small molecule specialty care, executing customer-facing and leadership roles in Research, Clinical Operations, Medical Affairs, Sales, Marketing and Commercial Asset/Portfolio evaluation.

His passion is equitable population health attainment through the integration of public and private sectors of health systems by the development of common language, measures, and goals along the tactic to impact continuum. He devised the Target Population Output (TPO) measurement, a common tool for public and private stakeholders to align population health and business goals. TPOs have been implemented and refined since 2020. In 2023 TPOs were introduced publicly in the context of the Harvard Health System Innovation Lab’s Strategic Public Private Partnership (SPPP) framework, and in 2024 this was presented, by Harvard, at the World Economic Forum, Davos, in a session hosted by them, Novartis and Novo Nordisk.

As Global Head of Clinical Practice at Boehringer-Ingelheim, Troels leads Global Medical Affairs Partnerships, Implementation Science and TPO teams. Troels continues to work on practical and pragmatic solutions for alignment and goal setting within the pharmaceutical industry to facilitate partnership and integration with health systems.

Based in Basel, Switzerland, Troels, has worked for several pharmaceutical companies including Roche, Johnson & Johnson, UCB, AstraZeneca, Takeda, and Novartis. He is an alumnus of the European Schools System, Oxford University, the British Medical Research Councils’ National Institute for Medical Research (now The Francis Crick Institute) and Warwick Business School.

After completing his medical studies and a Master’s Degree in Pharmacology in South Africa, Danie spent 3 years working in a primary care setting including his own private practice. He joined the pharmaceutical industry in 1993, worked in Medical Affairs, Marketing, Pharmacovigilance and Clinical Operations. He held roles of increasing responsibility and leadership, including Senior Vice President and Head of Worldwide Medical Affairs at GlaxoSmithKline. In 2019, Danie joined Kyowa Kirin International as the Executive Vice President for Medical Affairs, a role which he held until recently.

He is registered with the medical councils in the UK and South Africa and completed his MBA through Heriot Watt University and Edinburgh Business School in 2006. He is a Board Chair of the Medical Affairs Professional Society (MAPS) Board, and an affiliate member of the Association for Professional Executive Coaching and Supervision (APECS).

Following Graduation in Medicine at the Free University Berlin, Michael pursued a career in General, Cardiovascular and Surgical Oncology in Germany and the UK, gaining an MD and an FRCS.  He joined pharmaceutical industry 25 years ago and has since been in clinical development, project leadership, and commercial and medical affairs roles at country, regional and global level. To date, Michael leads the Medical Affairs Team of Novartis Oncology, Region Europe.
Throughout his industry career, Michael mainly covered specialty care areas, e.g. Oncology and Immunology. He also qualified as a Pharmaceutical Physician and as an MBA. Research interests and publications are in Oncology and Immunology as well as in general aspects concerning Medical Affairs and Medicine Development in the Industry.

Natasha Hansjee, PhD, is a global principal scientific communication director at Roche. She is also  an executive coach and a storyteller. She has over 20 years of pharmaceutical marketing experience: sales, local & global strategic product management; global product commercial strategy training; scientific communications; mentoring, coaching and facilitating - and has worked across all stages of the life cycle (early launch, launch, LoE). 

Joris van Vugt, Senior Medical Director at Viatris, studied Health Sciences at Maastricht University in The Netherlands and holds a Master in Pharmaceutical Medicine from Hibernia College in Dublin, Ireland.  He has over 20 years of experience in Medical Affairs in local, regional and global positions at Pfizer and since 3 years at Viatris. He currently focusses on strategic scientific partnerships to address unmet global health needs, including health equity, integration of care, human resources for health and capability development of the healthcare workforce.

SSourav is currently the Head of Global Services, Medical and Scientific Affairs at Boehringer Ingelheim. He leads the Medical and Scientific Affairs Communication services hub in the Barcelona delivery unit, supporting our Medical Affairs teams in HQ and regions execute on their scientific communication priorities across Field and digital channels at scale. He has over 18 years of experience in the industry and has held medical engagement strategy and execution roles across Life Science companies driving capability building and change at scale in complex big pharma matrix environments.

Nawab Qizilbash, MD DPhil, is CMO at OXON Epidemiology, a European-based full-service CRO specializing in real-world evidence strategy and studies. He is also Honorary Associate Professor in Epidemiology at the London School of Hygiene and Tropical Medicine. 

Currently, he collaborates extensively with Stuart Pocock, a renowned Professor of Medical Statistics, on projects that include significant publications (Lancets) and extension of the FDA-accepted Pocock Win Ratio from trials to RWE studies. He retains an affiliation with Green Templeton College, Oxford University.

Previously, Dr Qizilbash was Director, Clinical Epidemiology, GSK and was Honorary Consultant Physician in internal medicine at Oxford, working closely with the eminent Professor, Sir Richard Peto FRS on landmark epidemiological studies, as well as trials and meta-analysis

Chris Bassett is Sales Director for UK and Northern Europe at Springer Healthcare (part of the Springer Nature group).  Based in the UK, Chris started his Springer career as Commercial Partnership Manager, managing Springer’s relationships with key society and content stakeholders, such as ASCO and ASH.  In recent years, Chris has developed and now leads an expert team of educational content developers, delivering a wide range of solutions for healthcare professionals.   From in-person expert meetings and traditional print tools, through to interactive learning modules, live and on-demand webinars, and harnessing the power of digital opinion leaders.  Chris’s expertise lie in identifying the optimal content, delivered in the best format, to enact positive change for the healthcare industry.

Stuart Pocock is Professor of Medical Statistics (since 1989) at the London School of Hygiene and Tropical Medicine, a leading European centre of excellence for biostatistical research and teaching.

His primary research interest concerns clinical trials, both as regards methodological developments and applied collaboration in major trials, mainly in cardiology. He also has interests in observational epidemiology especially pharmaco-epidemiology. His particular methodological areas of expertise include: standards for the statistical reporting of trials and epidemiological studies, the statistical ethical and organisational principles for data monitoring including early stopping guidelines, the win ratio approach to a hierarchical composite of outcomes with clinical priorities, adaptive designs, handling non-proportional hazards, the value of repeat-event analyses, use and misuse of propensity scores, the pros and cons of non-inferiority trials, problems of multiplicity in trial reporting, eg, subgroup analyses, multiple outcomes and covariate adjustment, and the development/validation of prognostic risk scores.

Professor Pocock and his colleagues run a statistical centre for the design, conduct, analysis and reporting of major clinical trials, especially in cardiovascular diseases. He is also a consultant statistician for a wider range of clinical trials in which expert statistical advice is needed, and serves as a statistical member of many trial data monitoring and steering committees.

He collaborates internationally especially with the Centro Nacional de Investigaciones Cardiovasculares in Madrid, and the Cardiovascular Research Foundation and Mount Sinai School of Medicine in New York. He is a frequent lecturer on a variety of clinical trials issues, and has published over 600 articles in peer-reviewed journals, and a popular textbook “Clinical Trials: a Practical Approach''.